Lonza swoops in with $1.2B to take over Roche’s biologics site in California

Reynald Castañeda

Deputy Editor

With Lonza anticipating persistent increase in demand for commercial biologics manufacturing, the Swiss company is picking up a production site owned by Roche’s Genentech for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lonza swoops in with $1.2B to take over Roche’s biologics site in California

Reynald Castañeda

Deputy Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Lon­za swoops in with $1.2B to take over Roche’s bi­o­log­ics site in Cal­i­for­nia

Deputy Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Lonza swoops in with $1.2B to take over Roche’s biologics site in California